1
ALL1
Maxima PharmaceuticalsYear
1
ALL1
2022DEALS // DEV.
1
ALL1
DealsCountry
1
ALL1
CANADA1
ALL1
MediscaTherapeutic Area
1
ALL1
DermatologyStudy Phase
1
ALL1
ApprovedDeal Type
1
ALL1
AcquisitionProduct Type
1
ALL1
Small moleculeDosage Form
1
ALL1
GelLead Product
1
ALL1
Pluronic LecithinTarget
0
ALLLead Product(s) : Pluronic Lecithin
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Medisca
Deal Size : Undisclosed
Deal Type : Acquisition
Medisca Acquires all IP assets of Maxima Pharmaceuticals Including the DIFFUSIMAX® Brand
Details : Acquisition includes, DIFFUSIMAX® and DIFFUSIMAX®10 liposomal bases (pluronic lecithin organogel or PLO gel), products used for preparing compounded topical formulations, as well as all intellectual property assets of Maxima Pharmaceuticals.
Brand Name : Diffusimax
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 28, 2022
Lead Product(s) : Pluronic Lecithin
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Medisca
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?